NASDAQ$VCEL
Vericel Corporation · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported total revenue of $52.7 million with MACI revenue growth of 21% and NexoBrid revenue growth of 76% over prior quarter, achieved a gross margin of 70% and Adjusted EBITDA growth of 42%, and raised full-year profitability guidance.
Vericel Corporation reported a strong second quarter with record revenue driven by MACI and NexoBrid growth. The company raised its full-year profitability guidance due to strong performance.
- Total net revenue reached $52.7 million.
- MACI® net revenue grew by 21% to $44.1 million.
- Gross margin was 70%, an increase of 430 basis points versus the prior year.
- Non-GAAP adjusted EBITDA increased 42% to $6.3 million.
Headline financials
Revenue & EPS history
Vericel · Revenue · Quarterly
$52.7M
Revenue by segment
Vericel · $45.6M total across 3 segments · Q3 2023
- MACI$37.6M+21.3%82.5%
- Epicel$7.4M+1.4%16.2%
- NexoBrid$600K+200.0%1.3%
Forward guidance
Vericel reaffirmed total net revenue guidance of $238 to $242 million, representing 20% to 23% growth, and raised profitability guidance to 71% gross margin and 21% adjusted EBITDA margin.
Tailwinds
- Reaffirmed total net revenue guidance of $238 to $242 million, or 20% to 23% growth
- Profitability guidance raised to 71% gross margin
- Profitability guidance raised to 21% adjusted EBITDA margin
- The Company is very well-positioned for continued high revenue
- The Company is very well-positioned for continued high profit growth in 2024 and beyond
Headwinds
- Uncertainties associated with expectations regarding future revenue, growth in revenue, market penetration for MACI, Epicel, and NexoBrid
- The ability to continue to scale manufacturing operations to meet the demand for cell therapy products
- The timely completion of a new headquarters and manufacturing facility in Burlington, Massachusetts
- Potential fluctuations in sales and volumes and results of operations over the course of the year
- Supply chain disruptions or other events or factors affecting MediWound’s ability to manufacture and supply sufficient quantities of NexoBrid to meet customer demand
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+1.4%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+2.2%
Avg return
30 days after
47%
30 / 64 earnings
Positive
+48.1%
Q3 2018
Best reaction
-30.0%
Q2 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.6% | -10.4% | -1.4% | |
| Q4 2025 | +1.7% | -7.3% | -20.9% | |
| Q3 2025 | +4.6% | +10.3% | -2.6% | |
| Q1 2025 | +3.2% | +7.8% | +7.0% | |
| Q4 2024 | -6.1% | -3.2% | -15.8% | |
| Q3 2024 | +12.4% | +16.3% | +17.3% | |
| Q2 2024 | -5.7% | -7.5% | +2.2% | |
| Q1 2024 | -1.8% | -2.0% | -10.4% | |
| Q4 2023 | -6.5% | -7.0% | +8.8% | |
| Q3 2023 | -11.2% | -7.0% | -7.3% | |
| Q2 2023 | -8.9% | -9.2% | -3.5% | |
| Q1 2023 | +0.5% | +2.8% | +6.5% | |
| Q4 2022 | +6.9% | +6.6% | +1.6% | |
| Q3 2022 | -2.8% | +0.2% | -0.3% | |
| Q2 2022 | -4.3% | -6.2% | -28.7% | |
| Q1 2022 | -9.1% | -18.9% | -13.1% | |
| Q4 2021 | +21.9% | +26.4% | +11.2% | |
| Q3 2021 | -2.7% | -3.0% | -10.6% | |
| Q2 2021 | -2.1% | -4.5% | +9.0% | |
| Q1 2021 | -10.2% | -15.9% | -5.8% | |
| Q4 2020 | +0.4% | +1.7% | +9.0% | |
| Q3 2020 | +6.0% | +17.7% | +18.5% | |
| Q2 2020 | -9.8% | -5.0% | -5.5% | |
| Q1 2020 | +5.6% | +8.3% | +3.9% | |
| Q4 2019 | -20.4% | -18.3% | -46.9% | |
| Q3 2019 | +15.3% | +15.7% | +12.9% | |
| Q2 2019 | +2.4% | +1.9% | -8.3% | |
| Q1 2019 | -2.5% | -3.6% | -16.8% | |
| Q4 2018 | -7.4% | -3.5% | -13.6% | |
| Q3 2018 | +48.1% | +39.6% | +53.3% | |
| Q2 2018 | +25.6% | +27.1% | +36.5% | |
| Q1 2018 | +6.0% | +5.6% | +0.4% | |
| Q4 2017 | +40.1% | +38.3% | +33.5% | |
| Q3 2017 | -7.0% | -5.8% | +14.0% | |
| Q2 2017 | +11.7% | +21.7% | +48.3% | |
| Q1 2017 | +0.0% | +3.9% | +5.9% | |
| Q4 2016 | -1.7% | +0.0% | -6.9% | |
| Q3 2016 | -2.3% | +4.7% | +9.3% | |
| Q2 2016 | -5.5% | -7.7% | -5.5% | |
| Q1 2016 | +11.5% | — | — | |
| Q4 2015 | +4.8% | — | — | |
| Q3 2015 | -9.7% | — | — | |
| Q2 2015 | +4.3% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | +2.9% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q2 2014 | -0.3% | — | — | |
| Q1 2014 | +0.5% | — | — | |
| Q4 2013 | -12.7% | — | — | |
| Q3 2013 | -2.2% | — | — | |
| Q2 2013 | -30.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | -6.3% | — | — | |
| Q3 2012 | -4.0% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | -0.8% | — | — | |
| Q4 2011 | +1.0% | — | — | |
| Q3 2011 | +3.1% | — | — | |
| Q2 2011 | +8.3% | — | — | |
| Q1 2011 | +4.7% | — | — | |
| Q4 2009 | +4.7% | — | — | |
| Q3 2010 | +35.3% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +1.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro